Coherus Q2 LOQTORZI Revenue Climbs 15% Sequentially, Cash Runway Extended but Dilution Risk Lingers
CHRS sits 70% above its 52-week low of $0.81.
Summary
Coherus Oncology's Q2 2026 10-Q shows LOQTORZI revenue growing to $13.6M, a narrower loss, and $105.3M in cash — enough for 12 months but not to finish pipeline development, signaling future dilution risk.
Key Events · Earnings and Guidance · CHRS
-
LOQTORZI Revenue Growth
Driven by volume growth in nasopharyngeal carcinoma, Q2 2026 LOQTORZI net revenue reached $13.6 million, up 15% from Q1 2026 and 37% year-over-year.
-
Narrowing Losses
Reflecting lower R&D and SG&A expenses after biosimilar divestitures, net loss from continuing operations narrowed to $33.3 million in Q2 2026, compared to $44.9 million in Q2 2025.
-
Cash Runway and Future Funding Needs
Cash, equivalents, and marketable securities totaled $105.3 million at June 30, 2026. Management believes this funds operations for at least 12 months but not the completion of clinical trials through commercialization, requiring additional capital.
-
Option Repricing
On May 29, 2026, shareholders approved repricing 8.9 million underwater employee stock options to $1.59 per share and extending their term to 10 years, resulting in $6.3 million of incremental stock-based compensation expense recognized through May 2027.
Analysis · CHRS · Life Sciences
Coherus delivered Q2 2026 LOQTORZI revenue of $13.6 million, a 15% sequential gain, while narrowing its loss from continuing operations. Cash and equivalents sit at $105.3 million, which management says funds operations for at least 12 months but will not cover the full cost of clinical development through commercialization — meaning additional capital raises are likely. The company also repriced 8.9 million underwater employee stock options to $1.59, extending their term, which adds incremental stock-based compensation expense but avoids immediate dilution. The ATM program has $64.9 million remaining, and the UDENYCA earnout milestones have not been met, removing a potential near-term cash infusion. The combination of improving product sales and ongoing cash needs keeps the investment thesis balanced between commercial traction and financing risk.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CHRS was trading at $1.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $223.7M. The 52-week trading range was $0.81 to $2.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.